Get started
Novo Nordisk A/S Class BNovo Nordisk A/S Class BNovo Nordisk A/S Class B

Novo Nordisk A/S Class B

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsBondsETFs
Full chart
Full chart

Key facts today


Novo Nordisk: oral Wegovy hit 3 million prescriptions; 82% of prescribers are new to weight management. Studies at ADA backed GLP‑1 use. Shares fell 1% to DKK 280.20.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪159.80 B‬ EUR
Dividend yield (indicated)
4.14%
Price to earnings Ratio (TTM)
9.785
Basic EPS (TTM)
3.665 EUR
Net income (FY)
‪13.68 B‬ EUR
Revenue (FY)
‪41.29 B‬ EUR
Shares float
‪3.17 B‬
Beta (1Y)
1.00

Employees


Employees (FY)
‪68.79 K‬
Change (1Y)
‪−7.51 K‬ −9.84%
Revenue / Employee (1Y)
‪600.16 K‬ EUR
Net income / Employee (1Y)
‪198.91 K‬ EUR

About Novo Nordisk A/S Class B


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Maziar Mike Doustdar
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
Identifiers
2
ISIN DK0062498333
CFI code
ESVUFR
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NOV.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


4.277% YTM
Maturity date Nov 20, 2045
Coupon 4.00% (Fixed)
3.875% YTM
Maturity date Feb 20, 2038
Coupon 3.63% (Fixed)
3.826% YTM
Maturity date May 27, 2037
Coupon 3.63% (Fixed)
3.661% YTM
Maturity date Feb 20, 2035
Coupon 3.38% (Fixed)
3.543% YTM
Maturity date May 21, 2034
Coupon 3.38% (Fixed)
3.455% YTM
Maturity date May 27, 2033
Coupon 3.13% (Fixed)
3.366% YTM
Maturity date Feb 20, 2032
Coupon 3.00% (Fixed)
3.206% YTM
Maturity date Jan 21, 2031
Coupon 3.25% (Fixed)
3.175% YTM
Maturity date Aug 27, 2030
Coupon 2.88% (Fixed)
3.018% YTM
Maturity date Feb 20, 2029
Coupon 2.50% (Fixed)
2.984% YTM
Maturity date May 27, 2028
Coupon 2.38% (Fixed)

See all NOV bonds 

ETFs holding the stock


VXUS
Vanguard Total International Stock ETF
Weight 0.31%
Market value ‪1.98 B‬
VEA
Vanguard FTSE Developed Markets ETF
Weight 0.43%
Market value ‪1.32 B‬
IEFA
iShares Core MSCI EAFE ETF
Weight 0.57%
Market value ‪1.01 B‬
EFA
iShares MSCI EAFE ETF
Weight 0.66%
Market value ‪492.50 M‬
VGK
Vanguard FTSEEuropean ETF
Weight 0.86%
Market value ‪329.81 M‬
VEU
Vanguard FTSE All World Ex US ETF
Weight 0.34%
Market value ‪313.58 M‬
SCHF
Schwab International Equity ETF
Weight 0.49%
Market value ‪311.18 M‬
VIGI
Vanguard International Dividend Appreciation ETF
Weight 2.43%
Market value ‪223.21 M‬
IWDG
iShares Core MSCI World UCITS ETF Hedged GBP
Weight 0.15%
Market value ‪218.94 M‬
SWDA
iShares Core MSCI World UCITS ETF
Weight 0.15%
Market value ‪218.94 M‬
IWDD
iShares III PLC - iShares Core MSCI World UCITS ETF USD
Weight 0.15%
Market value ‪218.94 M‬

Explore more ETFs 

Frequently asked questions


The current price of NOV is 37.620 EUR — it has increased by 5.62% in the past 24 hours. Watch Novo Nordisk A/S Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange Novo Nordisk A/S Class B stocks are traded under the ticker NOV.
NOV stock has risen by 0.87% compared to the previous week, the month change is a −5.83% fall, over the last year Novo Nordisk A/S Class B has showed a −45.62% decrease.
We've gathered analysts' opinions on Novo Nordisk A/S Class B future price: according to them, NOV price has a max estimate of 60.59 EUR and a min estimate of 26.69 EUR. Watch NOV chart and read a more detailed Novo Nordisk A/S Class B stock forecast: see what analysts think of Novo Nordisk A/S Class B and suggest that you do with its stocks.
NOV reached its all-time high on Jun 26, 2024 with the price of 138.480 EUR, and its all-time low was 13.200 EUR and was reached on Jan 30, 2014. View more price dynamics on NOV chart.
See other stocks reaching their highest and lowest prices.
NOV stock is 2.48% volatile and has beta coefficient of 1.00. Track Novo Nordisk A/S Class B stock price on the chart and check out the list of the most volatile stocks — is Novo Nordisk A/S Class B there?
Today Novo Nordisk A/S Class B has the market capitalization of ‪167.86 B‬, it has decreased by −0.34% over the last week.
Yes, you can track Novo Nordisk A/S Class B financials in yearly and quarterly reports right on TradingView.
Novo Nordisk A/S Class B is going to release the next earnings report on Aug 5, 2026. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.88 EUR per share, whereas the estimation was 0.80 EUR resulting in a 10.54% surprise. The estimated earnings for the next quarter are 0.70 EUR per share. See more details about Novo Nordisk A/S Class B earnings.
Novo Nordisk A/S Class B revenue for the last quarter amounts to ‪9.35 B‬ EUR, despite the estimated figure of ‪9.29 B‬ EUR. In the next quarter, revenue is expected to reach ‪9.56 B‬ EUR.
NOV net income for the last quarter is ‪6.48 B‬ EUR, while the quarter before that showed ‪3.59 B‬ EUR of net income which accounts for 0.00% change. Track more Novo Nordisk A/S Class B financial stats to get the full picture.
Yes, NOV dividends are paid semi-annually. The last dividend per share was 1.06 EUR. As of today, Dividend Yield (TTM)% is 4.13%. Tracking Novo Nordisk A/S Class B dividends might help you take more informed decisions.
Novo Nordisk A/S Class B dividend yield was 3.60% in 2025, and payout ratio reached 50.75%. The year before the numbers were 1.83% and 50.28% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 11, 2026, the company has ‪68.79 K‬ employees. See our rating of the largest employees — is Novo Nordisk A/S Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo Nordisk A/S Class B EBITDA is ‪22.77 B‬ EUR, and current EBITDA margin is 48.43%. See more stats in Novo Nordisk A/S Class B financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo Nordisk A/S Class B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novo Nordisk A/S Class B technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novo Nordisk A/S Class B stock shows the strong sell signal. See more of Novo Nordisk A/S Class B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.